GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients benefit from treatment with GLP-1RAs. Initial results were presented at this year’s congress of the European Academy of Dermatology and Venereology (EADV).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Idiopathic and progressive pulmonary fibrosis (IPF/PPF)
An instrument for clinical use
- Rosacea - multifaceted and multifactorial
Topical and systemic active ingredients: proven and new therapeutic approaches
- Lung cancer
Multidisciplinary teams in oncology
- From diagnostics to personalized therapy
Nuclear medical imaging for Parkinson’s disease
- Psoriasis in difficult localizations: Nail psoriasis
IL-23 and IL-17 as a target – selected study findings
- Artificial intelligence in diabetes prevention
Lifestyle interventions are better accepted with AI
- B-cell lymphomas
Bispecific antibodies – mechanisms, evidence and future role
- Dermatoscopic findings of granulomatous diseases